HSBC Holdings
IBRX icon

HSBC Holdings’s ImmunityBio IBRX Stock Holding History

HSBC Holdings’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$398K Buy
+45,503
New +$344K ﹤0.01% 2386
2026
Q1 		– Sell
-86,141
Closed -$168K – 3062
2025
Q4 		$168K Hold
86,141
– – ﹤0.01% 2721
2025
Q3 		$211K Buy
86,141
+46,900
+120% +$121K ﹤0.01% 2473
2025
Q2 		$103K Sell
39,241
-3,163
-7% -$8.51K ﹤0.01% 2844
2025
Q1 		$126K Buy
42,404
+25,564
+152% +$77.5K ﹤0.01% 2747
2024
Q4 		$43.9K Buy
+16,840
New +$70.2K ﹤0.01% 3007
2024
Q3 		– Sell
-11,545
Closed -$73.8K – 3057
2024
Q2 		$73.8K Buy
11,545
+999
+9% +$6.59K ﹤0.01% 2784
2024
Q1 		$56.6K Buy
+10,546
New +$47.8K ﹤0.01% 2925

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HSBC Holdings's IBRX Position: Q2 2026 in Review

HSBC Holdings opened a new position in ImmunityBio (IBRX) in Q2 2026: 45,503 shares worth $398K. The stake represents ﹤0.01% of the portfolio and ranks #2386 among its holdings. This is a return to the name: HSBC Holdings previously reported a position in IBRX as recently as Q4 2025.

HSBC Holdings first reported a position in IBRX in Q1 2024 and has held it in 8 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • HSBC Holdings held 45,503 shares of ImmunityBio worth $398K as of Q2 2026.
  • ImmunityBio was a new HSBC Holdings position in Q2 2026.
  • ImmunityBio made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2386 holding.
  • HSBC Holdings first reported a position in ImmunityBio in Q1 2024 and has held it in 8 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.